ArticleJournal of diabetes research2026
Role of Systemic Factors in the Progression to Vision-Threatening Diabetic Retinopathy in a New Mexican Patient Population with Type 2 Diabetes: Glycemic Control Is Not Enough.
Article in Journal of diabetes research, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Purpose: The purpose of this study is to identify associative factors of vision threatening complications of diabetic retinopathy (DR), including proliferative diabetic retinopathy (PDR) and diabetic macular edema (DME) in a New Mexican patient population with Type 2 diabetes featuring a high proportion of Hispanic and American Indian patients. Methods: In a retrospective, case-control, cross-sectional study, we performed both univariate and multivariate logistic regression testing of systemic factors for association among patients with nonproliferative diabetic retinopathy (NPDR) without DME, NPDR with DME, and PDR. We also used receiver operating characteristic (ROC) curves to understand how reliable glycemic control is at predicting DR end-complications. Results: Among our 584 patients, 172 were diagnosed with NPDR without DME, 293 with PDR, and 119 with NPDR with DME. A total of 25% of patients with NPDR without DME had poor glycemic control (HbA1c levels of ≥ 9.0%). Similarly, 10% of PDR and 7% of NPDR with DME patients had good glycemic control (HbA1c levels ≤ 7.0%), despite their advanced eye disease. For patients with PDR, we identified significant independent associations with microalbuminuria and macroalbuminuria, Hispanic ethnicity, duration of diabetes, and the use of insulin and beta-blocker medications. In NPDR with DME patients, significant associations were noted with microalbuminuria and macroalbuminuria, HbA1c, GFR, and beta-blocker medications. The hemoglobin A1c level was not significantly associated with PDR but was significantly associated with NPDR with DME. The ROC curve analysis indicated poor predictability for the HbA1c model concerning the presence of PDR (AUC = 0.640) and NPDR with DME (AUC = 0.640). Conclusions: This study suggests that glycemic exposure alone is not a good enough predictor of DR progression. Other diabetic microvascular complications such as nephropathy, in addition to race/ethnicity with differing genetic associative factors, may also play a role in the multifactorial progression through DR phenotypes.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.